Actinium Pharmaceuticals, Inc.

Submit Your Information

Company Name	Actinium Pharmaceuticals, Inc.
Stock Symbol	ATNM

On August 5, 2024, before market hours, Actinium issued a press release providing an update on the planned Biologics License Application (“BLA”) filing for its radiotherapy product, Iomab-B, revealing that the FDA had determined that “the analyses from the [Phase 3 “Sierra Trial”] do not adequately support a BLA filing for Iomab-B and requires an additional clinical study.”

On this news, Actinium’s stock price fell $3.69, or 59.8%, to close at $2.48 per share on August 5, 2024, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Actinium Pharmaceuticals, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments